scholarly journals Genome Editing with Engineered Nucleases in Economically Important Animals and Plants: State of the Art in the Research Pipeline

2017 ◽  
Keyword(s):  
Genome Editing ◽  
State Of The Art ◽  
Engineered Nucleases

Adenoviral vector DNA for accurate genome editing with engineered nucleases

2014 ◽  
Vol 11 (10) ◽  
pp. 1051-1057 ◽  
Author(s):  
Maarten Holkers ◽  
Ignazio Maggio ◽  
Sara F D Henriques ◽  
Josephine M Janssen ◽  
Toni Cathomen ◽  
...  
Keyword(s):  
Genome Editing ◽  
Adenoviral Vector ◽  
Engineered Nucleases ◽  
Vector Dna

scholarly journals Genome Editing with Engineered Nucleases in Plants

2014 ◽  
Vol 56 (3) ◽  
pp. 389-400 ◽  
Author(s):  
Y. Osakabe ◽  
K. Osakabe
Keyword(s):  
Genome Editing ◽  
Engineered Nucleases

Prime editing: The state-of-the-art of genome editing

Meta Gene ◽  
2020 ◽  
Vol 24 ◽  
pp. 100661
Author(s):  
Fatemeh Khatami ◽  
Maryam Aghaii ◽  
Seyed Mohammad Kazem Aghamir
Keyword(s):  
Genome Editing ◽  
State Of The Art ◽  
The State

Therapeutic genome editing with engineered nucleases

2017 ◽  
Vol 37 (01) ◽  
pp. 45-52 ◽  
Author(s):  
Simone Haas ◽  
Viviane Dettmer ◽  
Toni Cathomen
Keyword(s):  
Gene Therapy ◽  
Genome Editing ◽  
Genetic Disorders ◽  
Zinc Finger Nucleases ◽  
New Era ◽  
Engineered Nucleases ◽  
Genetic Interventions ◽  
Type Gene ◽  
Programmable Nucleases ◽  
Cancer Immunotherapies

SummaryTargeted genome editing with designer nucleases, such as zinc finger nucleases, TALE nucleases, and CRISPR-Cas nucleases, has heralded a new era in gene therapy. Genetic disorders, which have not been amenable to conventional gene-addition-type gene therapy approaches, such as disorders with dominant inheritance or diseases caused by mutations in tightly regulated genes, can now be treated by precise genome surgery. Moreover, engineered nucleases enable novel genetic interventions to fight infectious diseases or to improve cancer immunotherapies. Here, we review the development of the different classes of programmable nucleases, discuss the challenges and improvements in translating gene editing into clinical use, and give an outlook on what applications can expect to enter the clinic in the near future.

scholarly journals Oligonucleotide-Mediated Genome Editing Provides Precision and Function to Engineered Nucleases and Antibiotics in Plants

2016 ◽  
Vol 170 (4) ◽  
pp. 1917-1928 ◽  
Author(s):  
Noel J. Sauer ◽  
Javier Narváez-Vásquez ◽  
Jerry Mozoruk ◽  
Ryan B. Miller ◽  
Zachary J. Warburg ◽  
...  
Keyword(s):  
Genome Editing ◽  
Engineered Nucleases ◽  
And Function

scholarly journals Next-Generation Gene Therapy for Parkinson’s Disease Using Engineered Viral Vectors

2021 ◽  
pp. 1-9
Author(s):  
Tomas Björklund ◽  
Marcus Davidsson
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Genome Editing ◽  
Viral Vectors ◽  
State Of The Art ◽  
The State ◽  
Next Generation ◽  
Suitable Vector

Recent technological and conceptual advances have resulted in a plethora of exciting novel engineered adeno associated viral (AAV) vector variants. They all have unique characteristics and abilities. This review summarizes the development and their potential in treating Parkinson’s disease (PD). Clinical trials in PD have shown over the last decade that AAV is a safe and suitable vector for gene therapy but that it also is a vehicle that can benefit significantly from improvement in specificity and potency. This review provides a concise collection of the state-of-the-art for synthetic capsids and their utility in PD. We also summarize what therapeutical strategies may become feasible with novel engineered vectors, including genome editing and neuronal rejuvenation.

scholarly journals CRISPR/Cas Technologies and Their Applications in Escherichia coli

2021 ◽  
Vol 9 ◽  
Author(s):  
Huina Dong ◽  
Yali Cui ◽  
Dawei Zhang
Keyword(s):  
Escherichia Coli ◽  
Transcriptional Regulation ◽  
Homologous Recombination ◽  
Genome Editing ◽  
State Of The Art ◽  
Bacterial Species ◽  
The State ◽  
Research Progress ◽  
End Joining ◽  
Eukaryotic Organism

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) systems have revolutionized genome editing and greatly promoted the development of biotechnology. However, these systems unfortunately have not been developed and applied in bacteria as extensively as in eukaryotic organism. Here, the research progress on the most widely used CRISPR/Cas tools and their applications in Escherichia coli is summarized. Genome editing based on homologous recombination, non-homologous DNA end-joining, transposons, and base editors are discussed. Finally, the state of the art of transcriptional regulation using CRISPRi is briefly reviewed. This review provides a useful reference for the application of CRISPR/Cas systems in other bacterial species.

scholarly journals State‐of‐the‐art CRISPR /Cas9 Technology for Genome Editing in Trypanosomatids

2019 ◽  
Vol 66 (6) ◽  
pp. 981-991 ◽  
Author(s):  
Noelia Lander ◽  
Miguel A. Chiurillo
Keyword(s):  
Genome Editing ◽  
State Of The Art
Sign in / Sign up

Export Citation Format

Share Document